This is a undervalued diversified consumer staple that plays to the aging boomer theme. They also have two new drugs in Phase III to expand the REMACAID family. For cancer they are developing YONDELIS and ZARNESTRA. They also have three drugs in development to treat HIV.

This is a undervalued, well run, nat gas E&P. They have recently had a well come in at 9 million cu-ft gas per day. They continue to expand at a high rate.

This is a high yielding stock in the process of unlocking value by spinning off PMI and KFT.

This is a good yielding diversified bank without a lot of mortage exposure.

This is a good yielding, growth utility.

Vista and Office upgrade cycle should help drive earnings until 2008-2009.

This is a consumer staple, pays a 3% divi and potential turnaround play.

This is a content play that is now developing content for china's market. They are also producing animations for India's growing market using Ballywood actors voices.